Indian stocks: Visit www.stage2stocks.com →

Silence Therapeutics Plc

Stage 2 · Advancing · week 13→2 today

As of Oct 22, 2026, Silence Therapeutics is in Stage 2, the uptrend phase, now in its first week (since Oct 22, 2026). It closed at $19.66, at its 52-week high and above its 200-day average, which is rising.

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of spe… More about the company

$19.66
+0.25% today
$1.2B · Small cap
Market Neutral — Fading

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is SLN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S2 29w
S3 14w
S4 28w
S2 25w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 1w → S1 8w → S2 29w → S3 14w → S4 10w → S1 2w → S4 28w → S1 12w → S2 1w → S3 7w → S2 11w → S3 5w → S4 6w → S1 3w → S2 25w → S3 1w → S2 1w current
Total tracked: 164 weeks across 17 stage runs.

SLN among Biotechnology29th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…29SLNStage 2 · wk 197+70.8%
vs 52W High
0.0%
$4.30 lo$19.66 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 1
1w13w26w
Week 1, fresh breakout
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
127.6%
200 DMA: $8.64 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
1.11x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+70.8%
3M
+78.4%
6M
+150.8%
YTD
+219.7%
1Y
+165.7%
Scan Membership
Breakout Watch
Latest: 2023-10-16
3 appearances in last 60 days. First seen: 2021-06-23.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S23→2
Wk 1 · Vol 1.11x
2026-10-21S3
Wk 1 · Vol 0.98x
2026-10-20S3
Wk 1 · Vol 4.93x
2026-10-19S3
Wk 1 · Vol 51.28x
2026-10-16S3
Wk 1 · Vol 0.82x
2026-10-15S32→3
Wk 1 · Vol 1.91x
2026-10-14S2
Wk 25 · Vol 0.93x
2026-10-13S2
Wk 25 · Vol 1.11x
2026-10-12S2
Wk 24 · Vol 0.42x
2026-10-09S2
Wk 24 · Vol 0.65x
2026-10-08S2
Wk 24 · Vol 0.85x
2026-10-07S2
Wk 24 · Vol 1.02x
Moving averages & range
50 DMA
$12.77
200 DMA
$8.64
52W High
$19.66
52W Low
$4.30
5D Low
$8.68
Resistance levels (recent highs)
20d High
$19.66
60d High
$19.66
120d High
$19.66
250d High
$19.66
Next resistance
Above all
ROE
-90.4%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 24.2

Silence Therapeutics: quick answers

What stage is Silence Therapeutics in?

As of Oct 22, 2026, Silence Therapeutics (SLN) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 22, 2026 and is in its first week there. What the four stages mean

Is Silence Therapeutics in an uptrend?

Yes. Silence Therapeutics is in a Stage 2 uptrend. It trades 127.6% above its 200-day average, which is rising.

How far is Silence Therapeutics from its 52-week high?

Silence Therapeutics closed at $19.66 on Oct 22, 2026, at its 52-week high. Its 52-week low is $4.30.

How has Silence Therapeutics performed over the past year?

As of Oct 22, 2026, Silence Therapeutics is up 165.7% over the past year and up 219.7% so far in 2026.

Which sector and industry is Silence Therapeutics in?

Silence Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.